Cancer

Cancer Specific MDx

Detect, Characterize. Genomic research continues to identify mutations associated with specific cancers and, in combination with clinical research, to identify their clinical relevance to a specific cancer and the prognosis/treatment for patients. While some mutations may be pathogenic, some are benign. Mutation profiling allows us to identify which mutations are present, determine clinical significance of those mutations, and identify pathogentic mutations with actionable therapies. To this end, mutation profiling using next generation sequencing and targeted cancer-specific panels allows us to detect mutations across multiple genes simultaneously and to screen patient susceptibility to a specific cancer.

Targeted Cancer MDx

Targeted Cancer, Targeted SOLUTIONS. Through genomic research, we continue to learn more about the complexity of cancer. While cancer continues to be identified by its location in the body (lung, breast, blood, etc.), we have learned that a more accurate way to evaluate cancer treatment is through examination of the underlying changes or mutations which drive cancer development and progression. Those mutations are not limited to location and, in many instances, have very little correlation with the location.